Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Allyson Ocean, ​MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

Allyson Ocean, MD, discussed the importance of clinical trials and how they should not be viewed as a last resort for patients with metastatic pancreatic cancer.

Gagandeep Brar, MD, discusses how the treatment paradigm has expanded in hepatocellular carcinoma, continuing sequencing challenges, and ongoing trials that are expected to impact the landscape.

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in ​locally advanced or metastatic esophageal carcinoma.

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

Allyson Ocean, ​MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer. 

Allyson Ocean, MD, discusses the encouraging results from the phase II TYME-88-Panc study of SM-88 in patients with advanced pancreatic cancer.

Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.

Anna C. Pavlick, DO, discusses common and uncommon adverse effects with cemiplimab in patients with cutaneous squamous cell carcinoma.

John P. Leonard, MD, discusses the FDA approval of tazemetostat in follicular lymphoma.

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.